Despite the fact that the US stock market has slightly declined this week, the three main indexes as well as the OTCQX Composite are fluctuating near their all-time highs, following a rebound in the economic growth, which returned to the pre-pandemic levels in July.
The labor market, which has been among the main concerns along with higher-than-expected inflation, is showing robust signs of improvement. On Thursday, the Labor Department said that the number of US citizens applying for unemployment benefits dropped to a 17-month low last week, suggesting another month of robust job growth.
Jobless claims fell 29,000 to a seasonally adjusted 348,000 for the week ended August 14, which is the fourth straight weekly decline.
Meanwhile, US equity funds secured their biggest inflow in about two months in the week ending August 18, driven by optimism over corporate profits and the improving US economy.
While more companies are recovering their operations despite the spread of the Delta variant, this is a great time to invest in stocks, and penny stocks are the best option given that they can deliver much higher and sometimes more rapid returns compared to blue chips.
OTC MARKETS THE PLACE TO BE
There are many good OTC stocks that can boost your portfolio’s value in the long term. For investors, we preach the key to trading hot OTC stocks is finding momentum BEFORE it happens and then be patient.
We alert our subscribers with our best ideas before our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here.
If you watch the Insider Financial YouTube channel, you can get a sense of the ideal time to book profits. We warned our subscribers not to get greedy or get caught up in the diamond hands/paper hands BS.
We also recommend you own a portfolio of OTC stocks. For some, that can be as many as 10 to 20 or more OTC stocks. This provides diversification and allows one to manage the market’s moods much easier. It also helps to own shares in the following 4 trending OTC stocks gaining momentum.
In this article, we look at 4 penny stocks on the rise that will greatly reward patient investors. They are Regen BioPharma, Inc (OTCPK: RGBP), NaturalShrimp, Inc (OTCQB: SHMP), Therapeutic Solutions International, Inc (OTCPK: TSOI), and Social Life Network, Inc (OTCPK: WDLF).
Penny Stocks Gaining Momentum #1: RGBP
Regen BioPharma, Inc, one of our favorite OTC stocks, has been on the rise in August. The share price increased from $0.015 on August 2 to the current level of $0.0388, which is the highest since mid-April, when RGBP was pulling back from its year-to-date high touched earlier that month at almost $0.06.
The key thing to know about this biotech firm is that it has several pending patents that it can potentially monetize in the long term.
The company finally released its Q1 report with some delay, and it will wait for the “Delinquent SEC Reporting” symbol to be removed from OTC Markets. The penny stock is about to become Pink Current, after getting the Pink Limited Information status earlier this week.
Speaking about the 10-Q report itself, the main thing that got our attention is that Regen has generated net losses of $14.5 million during the period from April 24, 2012 (inception) through March 31, 2021. The company said that its continuation was dependent on its ability to meet its obligations, to obtain additional financing as may be required, and ultimately to attain profitability, which we’re confident that it will manage to achieve. The management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the company will use or how much capital it will raise.
RGBP is focused on the immunology and immunotherapy space. At the moment, RGBP is focused on small molecule therapies for treating cancer and autoimmune disorders. On top of that, Regen is working on translational medicine platforms for the commercialization of stem cell therapies. The company produces stem-based medicines for diabetes, heart-related illness, circulatory issues, and Chronic Obstructive Pulmonary Disease. The stem cell industry is expected to exceed $15 billion by 2027.
Earlier this year, RGBP signed two deals with Oncology Pharma, which rose over 4,000% year-to-date. One deal focuses on treating pancreatic cancer, and the other one is for the treatment of colon cancer.
Investors expect that Oncology, Precigen, or another candidate will soon buy Regen. Still, this OTC stock is a great buy in itself.
1. Pink Limited Today
2. mRNA cancer vaccine approved by US government 2 days ago (took 5 years)
3. Patents being revived
4. Pink Current ASAP
5. We already have licensing agreements for the treatment of pancreatic and colon cancer.
6. More coming
7. Buyout🤫 pic.twitter.com/ffxL1qd4oE
— jtb3 (@jtb36) August 19, 2021
Penny Stocks Gaining Momentum #2: SHMP
NaturalShrimp, Inc has been rapidly increasing since Wednesday, when the OTC stock touched the lowest level since December 2020. SHMP is currently trading at $0.36, up about 40% during the last five days. The penny stock has recovered the losses incurred since mid-July, but it still trades close to its YTD low.
Insider Financial readers may know about SHMP, as we occasionally discussed it last year. For example, in May 2020, we presented our bullish case for the penny stock when it was trading at $0.06. Eventually, the share price peaked in February of this year at over $0.80, exceeding our previous estimates. However, the OTC stock has corrected since then, bottoming out last week.
After months of bearish mood, SHMP may switch tone. The aqua-tech company has developed the first commercially viable system for growing shrimp in enclosed, salt-water systems, using patented technology to produce fresh, never frozen, naturally grown shrimp, without the use of antibiotics or toxic chemicals. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp.
Last month, SHMP filed a new patent application with the USPTO to expand its electrocoagulation technology as applied to aquaculture both domestically and internationally. The original United States patent 10,163,199 “Recirculating Aquaculture System and Treatment Method for Aquatic Species” was awarded jointly to NaturalShrimp, Inc. and F&T Water Solutions, LLC on December 25, 2018. NaturalShrimp, Inc. recently acquired the assets of F&T Water Solutions, LLC on May 20, 2021, therefore providing NaturalShrimp, Inc. with 100% ownership of patent 10,163,199.
The new patent application now includes enhancements to the original patent based on novel improvements realized since applying the electrocoagulation technology for shrimp production over the last several years.
The company’s CTO, Tom Untermeyer, said:
“I see our patented technology as the key to making recirculating aquaculture systems for aquatic species (not just shrimp) sustainable and profitable. It’s important for the company and for our shareholders to protect our developing platform technologies worldwide by continuing to submit new and innovative patent applications.”
Meanwhile, the company changed its headquarters in Dallas given the accelerated growth and appointed Marco Van Den Berg to lead its sales and marketing activities, with responsibility for business in North America.
With no major debt and patented technology, SHMP is poised to reverse its long-term bearish trend. On top of that, the OTCQB company with a market cap of $220+ million is aiming to get listed on NASDAQ.
✅cleared all convertible debt
✅bought back preferred shares
✅two acquisitions completed
✅6million in cash
All this pre-revenue, and they mitigated the need to issue more shares. https://t.co/H7In7qjL11
— Follow the water, follow the money 🍤🚀💧🐟⛈ (@Overheard_PMO) August 16, 2021
In the fourth quarter of this year, SHMP expects weekly production at its facility in Texas, and this is when revenue will explode.
This is the right time to get SHMP at a bargain price.
Penny Stocks Gaining Momentum #3: TSOI
Therapeutic Solutions International, Inc has been confidently accelerated its uptrend after bottoming out at the end of July at about three cents, which was the lowest level year-to-date. The OTC stock has surged about 250% during the last month and is now trading at $0.11, which is the highest since mid-March. The share price is not very far from the YTD peak at $0.15. Prior to that, the OTC stock used to fluctuate near one cent for years.
TSOI initially surged early in August when the Food and Drug Administration (FDA) had given it the green light to start a Phase III pivotal trial for registration of its JadiCell™ universal donor stem cell as a treatment for COVID-associated lung failure.
The company said that it had previously demonstrated the superior activity of JadiCell to other types of stem cells, including bone marrow, adipose, cord blood, and placenta. TSOI’s JadiCell was reportedly shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo-controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85, the survival rate was 91%.
On Monday, the company went even further and announced that it was about to apply for an Emergency Use Authorization (EUA) to the FDA for its JadiCells in the treatment of COVID-19 associated lung injury. Under this provision, the FDA may authorize unapproved medical products to be used in an emergency to treat serious or life-threatening diseases or conditions. In fact, the vaccine products from Pfizer and Moderna are also delivered under the EUA.
TSOI’s CMO Dr. James Veltmeyer said:
“The extremely promising preclinical data we are generating, as well as the previously published double-blind FDA clinical trial and most recently, FDA clearance to enter Phase III, strongly supports the rationale to file for Emergency Use Authorization.”
Meanwhile, on Wednesday, TSOI announced that it was filing a patent application describing the unique mechanism of action of its JadiCell universal donor stem cell. The company used an animal model of advanced lung inflammation, designed to replicate Delta Variant infection, to assess the importance of CD73 expressing T cells. It was found that JadiCell administration increased the number of these cells in treated animals and that depletion of these cells resulted in suppression of JadiCell activity. On top of that, administration of low dose interleukin-2, while alone provides no protection in the current model, potently increased the ability of JadiCells to protect from lung inflammation.
To my knowledge we are the first company to actually have data combining and #FDA cleared drug (interleukin-2) with a cell therapy based approach for #COVID-19," said Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor. $TSOI #Patent https://t.co/9IYdWzW7Lo
— TherapeuticSolutions (@TSOIsupplement) August 18, 2021
TSOI is expanding really fast and it is an exciting time to get exposure to this $200 million Pink Current firm before it turns into something really big.
During the last 48 hours, the company hired to veterans:
- Boris Reznik of Venvalo Group was added to the Advisory Board to provide relations, strategy, and regulatory leadership as TSOI advances development of JadiCell adult stem cell.
- Peter C Farrell, founder and chairman of a $40 billion company was added to the Advisory Board to accelerate TSOI’s science-based approach to the prevention of suicide.
The FDA approval for the last step of treatment review, the patent filing, and the application for the EUA are some big events for TSOI, and we are bullish on this OTC stock. Besides JadiCell, TSOI is working on the treatment of neurological diseases.
Penny Stocks Gaining Momentum #4: WDLF
Social Life Network, Inc is also on the rise. The OTC stock has increased by over 100% during the last five days and since the beginning of August, reaching the highest level since mid-June. WDLF is now trading at $0.0081.
The OTC stock has much room for growth, as it reached its year-to-date high at $0.035 in mid-February. We first discussed WDLF at the end of last year, well before the penny stock surged about 400% to the February peak.
WDLF, which recently became Pink Current, is a Technology Business Incubator (TBI) that, through individual licensing agreements, provides tech startups with seed technology development, legal and executive leadership, making it easier for startup founders to focus on raising capital, perfecting their business model, and growing their client base.
WDLF’s technology is an AI-powered social network and eCommerce platform that leverages blockchain technology to increase speed, security, and accuracy on the niche social networks that it licenses to the companies in its TBI.
WDLF generates its revenues through its TBI licensees by charging a 5% fee on their revenue and a 15% common stock stake in the TBI licensee if they reach the liquidity event of going public or selling their business.
The recent spike in the penny stock has been driven by the news that Social Life Network it launched its global decentralized social network and cryptocurrency division called Decentral Life, and rolled out its own Ethereum-based token with the ticker WDLF. The company’s CEO Ken Tapp said:
“We have officially launched the crypto-loyalty points application throughout our social networking platform. We have been working on this milestone for many years now but needed to have our Token launched before we could move forward with a full network rollout for each of our TBI licensees. With each licensee having a unique business plan, the loyalty points formula had to work for current and future licensees, while potentially making certain the utility value of the WDLF token increased over time.”
The company is now working on developing a new decentralized social networking platform to replace its current platform and filing a registered coin offering with the SEC.
WDLF is leveraging the fast-growing crypto trend, and this will provide great incentives in the long term.
Meanwhile, WDLF is seeking $45 million in total damages with its two ongoing lawsuits that go after toxic funders, who allegedly violated federal securities laws, which reflects the current CEO’s shareholder-oriented attitude and ambition.
All in all, the company has some solid fundamentals that will drive its price to new highs.
THE FINAL NOTE
All of the 4 OTC stocks discussed today are on the rise and are good stocks to hold. Nevertheless, our best advice is to be patient and enter the market during corrections. Buying dips and selling rips as swing trades remains the best strategy in the penny stock market. Still, whenever an OTC stock is in the middle of a bull run, we recommend our subscribers to book profits.
It’s very important to eye OTC stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.
Remember, all you need is one or two OTC stocks to succeed in order to crush the market averages.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.